|
STUDY
|
|
PRINCIPAL INVESTIGATOR
|
CONTACT
|
|
ALZHEIMERS
|
|
|
|
|
ELAN 301 and 302: A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab in Patients with Mild to Moderate Alzeheimer's Disease who are Apolipoprotein E4 Non-Carriers (ELAN301) and are Apoliproprotein E4 Carriers (ELAN 302)
IRB #H08-098; IRB Approval Date: 1/16/08
|
|
Alireza Minagar, MD
|
Jeanie McGee, Project Coordinator
Phone: 318.813.1481
Email: jmcgee@lsuhsc.edu
|
| ANTIVENIN LATRODECTUS (BLACK WIDOW) |
|
|
|
|
ANALATRO- A Phase III Multicenter Clinical Trial of Analatro [Antivenin Latrodectus (Black Widow) Equine Immune F (ab)2] in Patients with Systemic Latrodectism. Sponsor: Instituto Bioclon S. A. de C. V.; Calzada de Tlalpan #4687; Colonia Toriello Guerra; Tlalpan, Mexico, D.F.
IRB #H10-07608
|
|
Dr. Steven Conrad
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
CANCER
|
|
|
|
FEIST-WEILLER CANCER CENTER STUDIES
PLEASE CLICK ON THE LINK TO SEE A LISTING OF CANCER CLINICAL TRIALS |
|
|
FEIST-WEILLER CANCER CENTER STUDIES |
|
CARDIOLOGY |
|
|
|
|
Cardiomyopathy
Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy
IRB #H11-035; IRB Approval Date: 11/10/10
|
|
Dr. Kalgi Modi |
P.J. Thompson, RN
Phone: 318.675.4683
Email: pthom5@lsuhsc.edu |
|
BC22140A ROW:
Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)
IRB #H10-096; IRB Approval Date: 5/10/10
|
|
Dr. Roche Alecardio/ Dr. Kalgi Modi |
P.J. Thompson, RN
Phone: 318.675.4683
Email: pthom5@lsuhsc.edu |
|
Protocol No: EFC11319: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coronary Syndrome.
IRB # H11-038; IRB Approval Date: 11/10/10
|
|
Dr. Steven Levine |
Keri A. Lee, RN
Phone: 318.675.5592
Email: khall1@lsuhsc.edu
|
|
DIABETES AND CARDIOVASCULAR STUDY
|
|
|
|
|
DIABETIC KETOACIDOSIS:
Normasol vs. Versus Normal Saline Diabetic Ketoacidosis.
IRB #H06-104; IRB Approval Date: 3/27/06
|
|
Dr. Simon Mahler
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
EPILEPSY/SEIZURE STUDY
|
|
|
|
|
OV1012: A Double-blind, Placebo Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5, 1.0 mg/kg.day) in patients with Lennox-Gastaut Syndrome.
IRB #H08-038; IRB Approval Date: 12/4/07
|
|
Dr. Rosario Riel-Romero
|
Jeanie McGee, Coordinator
Phone: 318.813.1481
Email: jmcgee@lsuhsc.edu
|
|
EISAI E2007-304: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial
IRB # H08-142; Approval Date: 04-06-2009
|
|
Dr. Arun Kalra |
Jeanie McGee, Coordinator
Phone: 318.813.1481
Email: jmcgee@lsuhsc.edu
|
|
HEPATITIS STUDY
|
|
|
|
|
ELAD 206: EFFICACY AND SAFETY OF THE EXTRACORPOREAL LIVER ASSIST DEVICE (ELAD) IN SUBJECTS WITH ACUTE ON CHRONIC HEPATITIS (AOCH)
IRB #H10-044
|
|
Dr. Steven Conrad
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
HEPATITIS C:SCH 503034
In previously untreated subjects with chronic hepatitis C infected with genotype.
IRB #H07-054; IRB Approval Date: 1/16/07
|
|
Dr. John King
|
Dana Favot, RN
Phone: 318.675.5902
Email: dfavro@lsuhsc.edu
|
|
MULTIPLE SCLEROSIS STUDIES
|
|
|
|
|
CONFIRM: A placebo-controlled study comparing a new oral drug for MS (BG00012) to Copaxone for patients with relapsing-remitting multiple sclerosis with at least one relapse in the past 12 months and an MRI proving lesions consistent with MS. Study drug or (placebo) is free of charge for the duration of this two year study.
IRB #H08-011
|
|
Dr. Alireza Minagar
|
Katy Chalamidas, Coordinator
Phone: 318.813.1452
Email: kchala@lsuhsc.edu
|
|
CARE-MS-1: A study comparing alemtuzumab to Rebif in patients who are previously untreated for relapsing-remitting multiple sclerosis with at least one relapse in the past 12 months and an MRI proving lesions consistent with MS. Study drug (or placebo) is free of charge ot the patient.
IRB #H08-075
|
|
Dr. Alireza Minagar
|
Katy Chalamidas, Coordinator
Phone: 318.813.1452
Email: kchala@lsuhsc.edu
|
|
CARE-MS-2: A study comparing alemtuzumab to Rebif in patients who are previously untreated for relapsing-remitting multiple sclerosis who have had relapses on other MS medications. Study drug (or Rebif) will be provided to study participants free of charge for the duration of this two year study.
IRB #H08-077
|
|
Dr. Alireza Minagar
|
Katy Chalamidas, Coordinator
Phone: 318.813.1452
Email: kchala@lsuhsc.edu
|
|
EFC6260 Sanofi: An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis.
IRB #H08-076; Approval Date: 11-26-07
|
|
Dr. Alireza Minagar |
Katy Chalamidas, Coordinator
Phone: 318.813.1452
Email: kchala@lsuhsc.edu |
|
OTOLARYNGOLOGY
|
|
|
|
|
A Survey of Biomarker in Head and Neck Cancers
IRB#H96-417; Approval Date - 1/26/96
|
|
Dr. Cherie-Ann Nathan
|
Cheryl Clark, PhD
Phone: 318.675.6259
Pager: 318.675.7007 #2101
Email: cdixon@lsuhsc.edu
|
|
Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma
IRB #H06-109; Approval Date: 4/24/06
|
|
Dr. Cherie-Ann Nathan
|
Cheryl Clark, PhD
Phone: 318.675.6259
Pager: 318.675.7007 #2101
Email: cdixon@lsuhsc.edu
|
|
Prospective Trial on Return of Vocal Cord Mobility Predicting Response to Radiation +/- Chemotherapy
IRB #H08-072; Approval Date: 12/19/07
|
|
Dr. Cherie-Ann Nathan
|
Cheryl Clark, PhD
Phone: 318.675.6259
Pager: 318.675.7007 #2101
Email: cdixon@lsuhsc.edu
|
|
An exploratory Biomarker Trial of the Food Substances Curcumin C3 Complex® with or without Bioperine® in Subjects with Newly Diagnosed or Recurrent Head and Neck Squamous Cell Carcinoma
IRB #H08-181; Approval Date: 11/26/07
|
|
Dr. Cherie-Ann Nathan
|
Cheryl Clark, PhD
Phone: 318.675.6259
Pager: 318.675.7007 #2101
Email: cdixon@lsuhsc.edu
|
|
Prospective Study on Reflux in Heak and Neck Patients
IRB #H08-180; Approval Date: 7/28/08
|
|
Dr. Cherie-Ann Nathan
|
Cheryl Clark, PhD
Phone: 318.675.6259
Pager: 318.675.7007 #2101
Email: cdixon@lsuhsc.edu
|
|
The Role of PET Scans in Head and Neck Cancer
IRB #H09-053; Approval Date: 3/5/09
|
|
Dr. Cherie-Ann Nathan
|
Cheryl Clark, PhD
Phone: 318.675.6259
Pager: 318.675.7007 #2101
Email: cdixon@lsuhsc.edu
|
|
PARKINSON'S DISEASE STUDIES
|
|
|
|
|
Effects of Coenzyme Q10 in Parkinson's Disease-Phase III (QE3): The objective of this study, called 'QE3' is to evaluate the safety and effectiveness of high dosages of CoQ in slowing clinical decline in people who have early Parkinson's disease. CoQ is a naturally occurring substance in the body and is also a nutritional supplement. In previous studies CoQ has been well tolerated.
IRB #H08-134; Approval Date: 6/2/08; NCT00740714
|
|
Dr. Richard Zweig
|
LaBrillia Johnson, RN, Study Coordinator
Phone: 318.675.8157
Email: ljoh23@lsuhsc.edu
|
|
PROGENI:
Parkinson's Research: The Organized Genetics Initiative.
IRB #H06-149; IRB Approval Date: 6/26/06; NCT00086073
|
|
Dr. Richard Zweig
|
LaBrillia Johnson, RN, Study Coordinator
Phone: 318.675.8157
Email: ljoh23@lsuhsc.edu
|
|
PD LS-1:
A Multi-center, Double blind, Parallel Group, Placebo Group, Placebo-controlled Study of Creatine in Subjects with Treated Parkinson's Disease (PD) LS-1.
IRB #H07-033; Approval Date: 9/26/06; NCT#00449865
|
|
Dr. Richard Zweig
|
LaBrillia Johnson, RN, Study Coordinator
Phone: 318.675.8157
Email: ljoh23@lsuhsc.edu
|
|
ADVANCED PARKINSON’S DISEASE:
An Open-Label, 12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson’s Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson’s Disease Medications
IRB #H010-015; IRB Approval Date: NCT00335153 S187.3.004
|
|
Dr. Richard Zweig
|
LaBrillia Johnson, RN, Study Coordinator
Phone: 318.675.8157
Email: ljoh23@lsuhsc.edu |
|
PEDIATRIC OBSERVATION STUDY
|
|
|
|
|
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated with Deferasirox.
IRB #H09-146; Approval Date: 5/12/2009
|
|
Dr. Majed Jeroudi
|
Lora Todd
Phone: 318.675.6983
Email: ltodd@lsuhsc.edu
|
| PEDIATRIC STUDIES |
|
|
|
|
HOD2008: Reduced Duration Standford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma
IRB #H07-101
|
|
Dr. Majed Jeroudi |
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu
|
|
HOD05: Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin's Disease
IRB #H09-131; Approval Date: 4/22/2009
|
|
Dr. Majed Jeroudi |
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu
|
|
OS2008: A Study of Bevacizumab (Avastin), a Human Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination with Chemotherapy for Treatment of Osteosarcoma
IRB#H09-107; Approval Date: 3/4/2009
|
|
Dr. Majed Jeroudi |
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu
|
|
ERWINASE: Compassionate Use of Erwinase (ERWINIA L-ASPARAGINASE for injection) for Pediatric Patients Patients with Acute Lymphoblastic Leukemia or Non-Hodgkins Lymphoma (IND290)
IRB#H09-088; Approval Date: 1/7/2009
|
|
Dr. Majed Jeroudi |
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
SJHG04-Phase I/II of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients with Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma - SJHG04
IRB#H09-074; Approval Date: 1/7/2009
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
TOTXVI-Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia
IRB#H08-177; Approval Date: 8/25/2008
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
A5971-A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma
IRB#H07-129; Approval Date: 6/25/2007
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
ACNS0223 - A Pilot Study Using Carboplatin, Vincristine and Temozolomide for Children < 10 Years with Progressive/Symptomatic Low-Grade Gliomas
IRB#H07-035; Approval Date: 9/25/2006
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
Neuroblastoma Protocol 2005: Therapy for Children with Advanced Stage High-Risk.
IRB#H06-088; Approval Date: 2/22/2006
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
OSTEOSARCOMA 1999 (OS99) - A Study of Intensive Chemotherapy Utilizing Ifosfamide, Carboplatin, and Doxorubicin for Adjuvant Chemotherapy for Treatment of Osteosarcoma.
IRB#H04-107; Approval Date: 1/26/2004
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
HOD99-Risk Adapted Therapy for Pediatric Hodgkin's Disease
IRB#H01-012; Approval Date: 1/29/2001
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
TOTXV-Total Therapy Study XV For Newly Diagnosed Patients With Acute Lymphoblastic Leukemia.
IRB# H01-024; Approval Date: 2/19/2001
|
|
|
Linda Douglas, RN
Phone: 318.831.1090
Email: ldougl@lsuhsc.edu |
|
CPI-CL-012 A Multi-center, Randomized, Open-Label, Parallel, Active-Comparator, Multiple Dose Trial to Determine the Efficacy, Safety, and Pharmacokinetics of intravenous Ibuprofen in Pediatric Patients
IRB #H10-100
|
|
Dr. Steven Conrad
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
RENAL CELL TRIAL STUDY
|
|
|
|
|
WILEX Pharmaceuticals: A randomized double-blind Phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence.
IRB #H05-107; Approval Date: 7/26/05
|
|
Dr. Donald Elmajian
|
Kacey Langley Arnold, CCRP
Phone: 318.675.5655
Email:karnol@lsuhsc.edu
|
|
SCHIZOPHRENIA STUDIES
|
|
|
|
|
15 MONTH STUDY FOR ADULTS WHO HAVE BEEN DIAGNOSED WITH SCHIZOPHRENIA AND INCARCERATED
The primary objective of this Phase IV study is to compare the efficacy of paliperidone palmitate with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated. Protocol-defined treatment failure is defined as arrest, psychiatric hospitalization, increase in psychiatric services to prevent imminent hospitalization, discontinuation of antipsychotic treatment due to inadequate efficacy, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to safety or tolerability or completed suicide. Patients will receive either paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for fifteen months OR oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the study doctor.
IRB #H11-073; IRB Approval Date: 01/10/2011
|
|
Marc Colon, MD |
Lindsey Mann, BA/BS
Study Coordinator
Phone: 318.813.2070
Toll-Free: 1.866.779.2546
Email: lande6@lsuhsc.edu
Or
Angela Benedetto, MA
Outreach Coordinator
Phone: 318.813.2070
Toll-Free: 1.866.779.2546
Email: abened@lsuhsc.edu |
| SCLERODERMA STUDY |
|
|
|
|
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma, Protocol MI-CP200
Study participant must be 18 years or older with scleroderma with moderate skin thickening. Study drug (or placebo) provided by study.
IRB #H10-088, approval date 3/8/10
|
|
Dr. Samina Hayat |
Denise Shewmake, RN
Phone: 318.675.5585
Email: sshewm@lsuhsc.edu |
|
SEVERE SEPSIS STUDY
|
|
|
|
PRoCESS: Protocolized Care for Early Septic Shock
IRB #H10-095 |
|
Dr. Steven Conrad
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu |
|
ACCESS:
A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis.
IRB #H06-151 - Original approval: 8/7/06
|
|
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
STROKES STUDIES
|
|
|
|
|
WARCEF STROKE PREVENTION:
Stroke prevention in subjects with congestive heart failure. Ejection Fraction (EF) must be 35% or below. Study meds include warfarin/placebo or aspirin/placebo. There is no cost to the patient. Medication is regulated by blood collections at intervals determined by the study physician. Joint Neurology and Cardiology investigation.
IRB # H-02-020
|
|
Dr. Roger E. Kelley
|
Jeanie McGee, Coordinator
Phone: 318.813.1481
Email:jmcgee@lsuhsc.edu
|
|
IRIS:
Study for patients who have experienced a recent stroke (within the past 6 months) and who are insulin resistant (determined by a blood test). There will be no cost for study medication (pioglitazone or placebo) or for study visits.
IRB #H05-065; IRB Approval Date: 9/27/05
|
|
Dr. Alireza Minagar
|
Katy Chalamidas, Coordinator
Phone: 318.813.1452
Email: kchala@lsuhsc.edu
|
|
OTHER STUDIES
|
|
|
|
|
ADOPT: A Phase 3, Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization. Sponsor: Bristol Myers Squibb. June 2007 - Present.
IRB #06-160; IRB Approval Date: 6/26/06
|
|
Dr. Steven Conrad
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
"A Comparison of Anavip® [Crotalinae (pit viper) equine immune F(ab)2 ] and CroFab® (Crotalidae Polyvalent Immune Fab, ovine) in the Treatment of Patients with Crotalinae Envenomation: A Randomized Prospective, Blinded, Controlled, Comparative, Multi-center Study", (Anivip). Sponsored-Instituto Bioclon S.A. de C.V. May 2008-present.
IRB #H08-124; IRB Approval Date: 3/19/08
|
|
Dr. Thomas Arnold
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
Injuries Produced by Law Enforcement Use of Less Lethal Weapons: A Prospective Multi-center Trial.
IRB #H05-173; IRB Approval 5-11-05
|
|
Dr. Derell Graham
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|
|
NAC- A Multi-center, Double-blind, Randomized, Controlled Study to Determine the Efficacy and Safety of a New Formulation of Acetylcysteine Injection
Sponsor –Cumberland
IRB #10-116
|
|
Dr. Steven Conrad
|
Kimberly Hutchinson
Phone: 318.675.6682
Email: ksmit9@lsuhsc.edu
|